Patent · US Active

Blocking Hepatitis C Virus infection associated liver tumor development with HCV-specific antisense RNA

US10487328B2 · kind B2 · utility

0Cited by
1References
12Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMar 25, 2015
Grant dateNov 26, 2019
Priority date—
Expiry dateMar 25, 2035

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2320/51
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The disclosure teaches antagonists of Hepatitis C Virus (HCV) derived microRNA, which are useful in methods for treating and protecting against HCV-mediated hepatocellular carcinogenesis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.